131I in Blood Samples: A Danger for Professionals? A Problem for Immunoassays?

Journal of Nuclear Medicine Technology

Julie Vialard-Miguel¹  Agnès Georges¹  Dominique Ducassou¹  Joaquim Mazère¹  Jean-Benoît Corcuff¹ 

[1] Nuclear Medicine Department, University Hospital of Bordeaux and University Bordeaux 2, Bordeaux, France Nuclear Medicine Department, University Hospital of Bordeaux and University Bordeaux 2, Bordeaux, France Nuclear Medicine Department, University Hospital of Bordeaux and University Bordeaux 2, Bordeaux, France

关键词: radiobiology/dosimetry;    radioimmunoassay;    radionuclide therapy;    ¹³¹I;    radioprotection;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Objective: Our objective was to investigate the safety of radioactive blood samples from patients receiving 131I and whether the radioactivity affects the validity of assays.Methods: First, the activity of samples from patients given 131I was measured by 3 methods and compared with the upper threshold. Then, pilot sera were spiked with 131I, and possible interference was investigated using 2 immunoradiometric assays.Results: The activity of 13 of the 15 samples was below the European limit; the other 2 samples were from patients with reduced renal clearance rates. No differences in thyroglobulin level or thyroid-stimulating hormone level were found between sera that were spiked with 131I and sera that were not.Conclusion: These blood samples are safe because they contain negligible activity, and the use of radioimmunoassays or immunoradiometric assays on them produces reliable results.

【 授权许可】

Unknown